908 Devices (MASS) Leerink’s Global Healthcare Conference 2025 summary

Strategic transformation and portfolio focus

• Announced divestiture of biopharma desktop portfolio for $70 million, nearly doubling cash reserves and accelerating path to profitability.

• Sharpened focus on high-growth handheld markets, with revenue from handhelds outpacing desktops by two times since IPO.

• Expanded from one to four handheld products, integrating RedWave acquisition, and targeting six products by 2026.

• Revenue guidance for continuing operations set at $53–$55 million for 2025, representing 11–15% year-over-year growth.

• Targeting adjusted EBITDA positivity by Q4 2025 and full cash flow positivity in 2026.

Market opportunities and growth drivers

• Addressing a $2.5 billion total addressable market in health and safety, focusing on fentanyl, opioid crisis, and toxic threat detection.

• Three key growth catalysts: global equipment modernization, next-gen handheld mass spec launch, and U.S. DoD AVCAD program moving to full-rate production.

• International revenue now comprises about a third of total, with recent wins in EU stockpile programs and a $1.7 million order from Ukraine.

• Distribution channels in Europe, Middle East, and APAC drive international expansion, with discounts impacting margins but significant growth expected.

• AVCAD program could generate up to $10 million annually over five to seven years, with full-rate production decision expected by fiscal year-end.

Product innovation and recurring revenue

• Next-gen MX908 handheld mass spec to launch in 2026, featuring 50% reduction in size and weight, enhanced simplicity, and lower production costs.

• Expanded recurring revenue streams through connected services and fleet management applications, aiming to increase pull-through.

• RedWave acquisition broadened portfolio, enabling cross-selling and total solution pitches, with integrated sales teams driving growth.

• Pilot-to-enterprise strategy increased pilot units from 100 to over 700 in 2024, setting up future enterprise account conversions.

• Continued investment in innovation with new products and connected services, while maintaining exposure to broader life science applications.